French Trial Tragedy: Who Says What Data Should Be Published?
This article was originally published in Scrip
While French government inspectors pore over the results of their recent visit to the premises of Biotrial, the CRO that ran the ill-fated Phase I study with the FAAH inhibitor BIA 10-2474, the regulatory agency ANSM has revealed that the product's developer, Bial, has opposed the publication of the preclinical documentation on the drug.
You may also be interested in...
Pharmaceutical companies in the UK have again been asked to ensure they have contingency measures in place to deal with potential supply problems at channel ports – this time in preparation for the UK’s formal departure from the EU’s single market and customs union at the beginning of 2021. The industry is continuing to push for a mutual recognition agreement on drug regulation.
The UK BioIndustry Association has welcomed the government’s fresh investment in COVID-19 vaccine manufacturing capacity, while Sanofi and GSK are striking European and US deals for their vaccine candidate. A number of potential therapies are also being developed, including products based on interferon and hyperimmune globulin, but Roche/Chugai’s Actemra (tocilizumab) looks like a non-runner.
A parliamentary committee has come up with some ideas for strengthening the UK’s response to future demand surges due to the spread of COVID-19.